About Francesco

Dr Francesco Marinucci has more than 16 years’ experience managing global health programs and working closely with ministries of health, NGOs and manufacturers. He brings a unique mix of corporate, non-profit, academic research and laboratory management expertise to his new role at FIND.

Dr Marinucci graduated in Chemistry from the University of Rome La Sapienza, and completed his PhD in Public Health and Microbiology from the same institution, with a research study on the epidemiology and transmission patterns of HIV and other STDs among rural populations in sub-Saharan Africa. He also holds a postgraduate diploma in Clinical Biochemistry from the School of Medicine of the University of Rome, Tor Vergata. He held several positions in clinical laboratory hospitals, mainly in Microbiology and Hematology departments. He is member of different scientific societies and European Specialist in Laboratory Medicine since 2004.

From 2007 to 2012, Dr Marinucci worked at the Institute of Human Virology of the University of Maryland in Baltimore where he directed the Global Laboratory Program. In this position, he had oversight of a 20+ member team, providing strategic leadership and technical direction that the institute implemented under a PEPFAR grant in 9 countries. Under his leadership, the Global Laboratory Program supported 229 laboratories and trained hundreds of laboratory workers in the sub-Saharan African region, as well as in other PEPFAR countries in the Caribbean region. For the past five years, Dr Marinucci has been working as Director of Essential Healthcare with Partec GmbH, then with Sysmex Corporation. His major focus was on strategy and business development related to access to quality diagnostic products, and on establishing new partnerships with WHO, UN agencies, ASLM and USAID. He also serves as speaker for the German Healthcare Partnership on topics related to laboratory medicine in sub-Saharan Africa.

This speaker will be presenting at the following session(s)

  • Strategic direction 5: innovation for acceleration


    Day: 3 November

    Time: 14:00

    Innovation can help drive towards the overall objective of hepatitis elimination in a wide range of settings. This innovation session will highlight innovations related to hepatitis B and C products, programs and policies.


    • Introduction and importance of innovation.
    • Michael Ninburg, World Hepatitis Alliance
    • Innovation plenary.
    • Innovation panel.
    • Dr. Francesco Marinucci, Foundation for Innovative New Diagnostics
      Dr. Joseph Tucker, University of North Carolina
      Dr. Bobby John, Global Health Advocates
      Call for Submissions authors

    Session objectives:

    • Learn the importance of innovation in developing hepatitis B and C control programs, policies and products.
    • Understand new products for hepatitis B and C control that could accelerate detection, treatment and retention.
    • Discuss new policies for expanding access to hepatitis B and C testing, treatment and prevention strategies.
    • Learn about new programs and public health interventions to optimize comprehensive hepatitis care.
  • Unitaid’s role in hepatitis C

    Side meeting

    Day: 1 November

    Time: 17:30

    This evening side meeting presents Unitaid’s investment and operating model in the context of the emerging global response to hepatitis C. It will share the results of Unitaid-funded projects related to hepatitis C. It will also explore opportunities for potential future investments. 

    This early morning side meeting will look at


    • Opening remarks – Unitaid’s model and its relevance for Hepatitis C.
    • Where are we today?
    • Developing a simplified mode of care for HCV.
      Dr. Sabrina Sharmin, Médecins Sans Frontières
    • Creating demand and innovative solutions for access to HCV treatment.
      Khalil Elouardighi, Coalition Plus
    • Facilitating diagnostic solutions.
      Dr. Francisco Marinucci, Foundation for Innovative New Diagnostics
    • Putting the pieces together to maximise benefits.
      Dr. Marc Bulterys, World Health Organization
    • Moderated discussion.